BioAsset

Insights / All articles

Research

Update: BMS x Anthropic

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 1 slide

Bristol Myers Squibb has struck a deal with Anthropic to roll out Claude across the entire company. The rollout covers R&D, manufacturing, clinical development and commercial, all of it, and reaches more than 30,000 employees.

The point isn’t another chatbot. BMS is building AI directly into the day-to-day workflows that actually move drugs through the pipeline. A $120B pharma giant has gone this far, and the rest of the industry is certainly taking notes. The enterprise AI era in drug development has arrived.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.